|
gptkbp:instanceOf
|
antiviral drug
nucleotide
|
|
gptkbp:administeredBy
|
gptkb:physician
dextrose
saline
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:India
gptkb:Japan
gptkb:United_States
gptkb:FDA
2020
|
|
gptkbp:ATCCode
|
J05AB16
|
|
gptkbp:CASNumber
|
1809249-37-3
|
|
gptkbp:chemicalFormula
|
C27H35N6O8P
|
|
gptkbp:clinicalTrialPhase
|
gptkb:ACTT-1
gptkb:Solidarity_trial_(WHO)
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to remdesivir
|
|
gptkbp:cost
|
approximately $2,340 per course (US, 2020)
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:discoveredIn
|
2009
|
|
gptkbp:effectOnCOVID19
|
no significant reduction in mortality (per some studies)
shortens recovery time in some patients
|
|
gptkbp:eliminationHalfLife
|
1 hour (remdesivir), 25 hours (GS-441524 metabolite)
|
|
gptkbp:emergencyServices
|
granted by FDA (2020)
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:form
|
solution for injection
lyophilized powder
|
|
gptkbp:genericAvailable
|
yes (in some countries)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
remdesivir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits viral RNA-dependent RNA polymerase
|
|
gptkbp:metabolism
|
gptkb:GS-441524
liver
|
|
gptkbp:molecularWeight
|
602.6 g/mol
|
|
gptkbp:notOrallyBioavailable
|
true
|
|
gptkbp:notRecommendedFor
|
children under 12 years (in some regions)
|
|
gptkbp:patent
|
gptkb:Gilead_Sciences
|
|
gptkbp:pregnancyCategory
|
Not assigned (US)
|
|
gptkbp:PubChem_CID
|
121304016
DB14761
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
elevated liver enzymes
allergic reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:synonym
|
gptkb:GS-5734
|
|
gptkbp:UNII
|
R7XA6E0Z1L
|
|
gptkbp:usedFor
|
gptkb:COVID-19
gptkb:Ebola_virus_disease_(investigational)
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:COVID-19
gptkb:COVID-19_pandemic
|
|
gptkbp:bfsLayer
|
4
|